MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.72
+0.21 (2.00%)
At close: May 15, 2026, 4:00 PM EDT
10.07
-0.65 (-6.11%)
After-hours: May 15, 2026, 7:14 PM EDT
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
53.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 53.48M |
| Metagenomi Therapeutics | 22.33M |
| Radiopharm Theranostics | 10.86M |
| Hyperion DeFi | 813.46K |
| iBio, Inc. | 300.00K |
| aTyr Pharma | 190.00K |
INKT News
- 13 hours ago - MiNK Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 14 hours ago - MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation - GlobeNewsWire
- 1 day ago - MiNK Therapeutics initiates agenT-797 clinical trial - TheFly
- 1 day ago - MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - GlobeNewsWire
- 3 days ago - MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 - GlobeNewsWire
- 7 days ago - MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs - GlobeNewsWire
- 25 days ago - MiNK Therapeutics management to meet virtually with B. Riley - TheFly
- 6 weeks ago - MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - GlobeNewsWire